logo
Plus   Neg
Share
Email

Neurocrine Biosciences: Luvadaxistat Fails To Meet Primary Endpoint In Phase II INTERACT Study

Neurocrine Biosciences (NBIX) said the investigational drug luvadaxistat did not meet primary endpoint in the phase II INTERACT study in adults with negative symptoms of schizophrenia. Luvadaxistat met secondary endpoints of cognitive assessment.

Takeda Pharmaceutical Company granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including luvadaxistat, in June 2020.

Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences, said: "The totality of the top-line data from this study therefore support further clinical evaluation of luvadaxistat. We plan to work with our partner Takeda as we move forward."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Inter-American Development Bank and Citi Innovation Labs have successfully completed a proof-of-concept to make cross-border payments from the U.S. to countries in Latin America and the Caribbean, using blockchain and tokenized money. The platform provided full traceability of the transactions, exchange rates, and fees on blockchain. Australian competition regulator said the country's Federal Court found that Google and its Australian arm misled users about the collection and use of personal location data. The data was collected through Android mobile devices between January 2017 and December 2018. This is said to be the world-first enforcement action brought by the Australian Competition and Consumer Commission or ACCC. Morgan Stanley (MS) reported a first-quarter profit that more than doubled from last year, reflecting strong performance across all of its business segment. Net revenues for the quarter grew 61 percent from the previous year. Quarterly adjusted earnings per share beat analysts' estimates.
Follow RTT